Biogen BIIB FAMPYRA — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's fampyra — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's FAMPYRA — total revenue?
- Biogen (BIIB) reported FAMPYRA — total revenue of $0 in Q1 2026.
- How has Biogen's FAMPYRA — total revenue changed year-over-year?
- Biogen's FAMPYRA — total revenue decreased by 100.0% year-over-year, from $300K to $0.
- What is the long-term trend for Biogen's FAMPYRA — total revenue?
- Over 4 years (2021 to 2025), Biogen's FAMPYRA — total revenue has grown at a -66.0% compound annual growth rate (CAGR), from $105.3M to $1.4M.
- What does FAMPYRA — total revenue mean?
- This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic asset within the company's portfolio. It reflects the market demand, pricing power, and commercial adoption of the therapy for its indicated condition. Monitoring this revenue stream helps investors assess the product's lifecycle stage and its contribution to the overall top-line performance of the business segment.